Honestly, my man, you need to think broader. Looking at efficacy in isolation is a 2D way of thinking that caught a lot of investors here off-guard with HER-Vaxx and PD1-Vaxx.
This is just one example of the competition for market share Azer-cel must overcome. Approved for use in R/R DLBCL with >2 prior systemic therapies.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-lenalidomide-and-rituximab-relapsed-or-refractory-large-b-cell
Just look at how effective this newly approved combination was for patients with prior CAR T, with 62% Overall Survival and 59% Progression Free Survival benefit in comparison to standard treatment.
https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/b8d34c2d-cafa-4061-a970-59cef54354f9/Kim_OP_LBA7005_4_ASCO2024.pdf
"Responses were observed in patients regardless of CD30 status"
The shorters spend more time researching things like this, have run the calculations on market competition and size, and are more accurately evaluating IMU relative to retail holders.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $179.4K | 14.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 15731879 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3463196 | 20 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |